Sermorelin and Finasteride Interaction: What Women Need to Know

What Is the Interaction Between Sermorelin and Finasteride?

The short answer: there is no established high-severity pharmacokinetic interaction between sermorelin and finasteride. Neither drug is a substrate, inhibitor, or inducer of CYP3A4, CYP2C19, or P-glycoprotein in a way that affects the other's plasma levels. The risk that does exist is pharmacodynamic, meaning the two drugs act on overlapping physiological pathways, specifically androgen signaling and its downstream effects on growth hormone (GH) pulsatility, rather than competing for the same metabolic enzyme.

Understanding this distinction matters because a pharmacodynamic interaction is real, measurable, and clinically relevant, even though it will not appear as a flagged "interaction" in most standard drug databases.

How Sermorelin Works

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous GHRH. It binds the GHRH receptor on somatotroph cells in the anterior pituitary, stimulating pulsatile release of GH. The FDA reviewed sermorelin (brand name Geref) for growth hormone deficiency in children, though the branded product was discontinued. Today sermorelin is compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act and used off-label in adults for age-related GH decline, body composition, sleep quality, and, increasingly, female pattern hair loss (FPHL) via its anabolic effects.

Because sermorelin is a peptide, it is not metabolized by hepatic CYP450 enzymes. It is cleaved by circulating and tissue peptidases, predominantly in the kidney and liver, with a plasma half-life of approximately 10 to 20 minutes.

How Finasteride Works

Finasteride is an irreversible competitive inhibitor of type II (and, at higher doses, type III) 5-alpha reductase (5-AR). It blocks the conversion of testosterone to dihydrotestosterone (DHT). At 1 mg daily (Propecia), finasteride reduces scalp DHT by approximately 64% and serum DHT by approximately 68%. At 5 mg (Proscar), the reduction in serum DHT reaches approximately 70%.

Finasteride is metabolized primarily by CYP3A4 to inactive carboxylic acid and omega-hydroxy metabolites, with a half-life of 6 to 8 hours in younger adults and up to 8 hours in older individuals. It is neither a significant inhibitor nor inducer of CYP enzymes at therapeutic doses.

The Pharmacodynamic Overlap: Androgens and the GH Axis

This is where the interaction becomes clinically meaningful for women.

Androgens Modulate GH Secretion

Androgens, particularly testosterone and DHT, influence the GH/IGF-1 axis in multiple directions. Testosterone enhances GH pulse amplitude and increases IGF-1 production in the liver. This relationship has been documented in both male and female physiology, though female-specific data are thinner than male data. When finasteride lowers DHT, the net androgen signaling shifts. In women, where baseline androgens are already lower, this shift may attenuate the GH-stimulating effect of sermorelin to a modest degree.

No published randomized controlled trial has directly measured sermorelin response in women co-administered finasteride. This is an evidence gap. The available inference comes from:

1. Studies of androgen deprivation and GH axis suppression in prostate cancer populations (predominantly male, so extrapolation is required).
2. Studies of GH secretion across the menstrual cycle, showing that GH pulsatility varies significantly with estrogen and androgen fluctuations.
3. Pharmacological studies showing that GH secretagogues produce larger IGF-1 increments in individuals with higher baseline androgen tone.

DHT's Specific Role vs. Testosterone

Finasteride selectively blocks the conversion of testosterone to DHT but does not suppress testosterone itself. In fact, finasteride treatment raises total testosterone by roughly 10 to 15% as a compensatory response. For women on sermorelin, the net GH axis effect of finasteride may be neutral or even slightly favorable via the testosterone rise, partially offsetting any blunting from DHT reduction. The magnitude of this effect in women has not been directly studied.

Hair Loss as a Shared Endpoint

Female pattern hair loss is the most common context in which a woman might be prescribed both drugs simultaneously. FPHL affects approximately 40% of women by age 50, and both sermorelin (via IGF-1-mediated anabolic effects on the hair follicle) and finasteride (via DHT reduction at the follicle) are used off-label to slow or reverse it. The combination is sometimes used in clinical practice for women with FPHL who also have evidence of GH decline, particularly perimenopausal women, although no head-to-head or combination trial exists in women.

The WomanRx clinical framework for evaluating this combination uses three questions:

1. Is there a pharmacokinetic interaction that changes drug levels? Answer: No.
2. Is there a pharmacodynamic interaction that changes efficacy or safety? Answer: Yes, modest and indirect, through androgen-GH axis crosstalk.
3. Is the clinical outcome of the combination better, worse, or neutral compared with either drug alone for FPHL in women? Answer: Unknown; no trial data exist.

Life-Stage Considerations for Women

Reproductive Years (Ages 18 to 39)

Women of reproductive age considering finasteride must use reliable contraception. Finasteride is teratogenic to male fetuses. Exposure during the period of male genital differentiation causes ambiguous genitalia and hypospadias. This is a Category X teratogen for male fetal exposure and a Category X drug in any person who may become pregnant with a male fetus.

Sermorelin is Pregnancy Category C, meaning animal reproduction studies have shown adverse effects and there are no adequate human studies. Both agents should be stopped before any planned conception attempt.

Women in their reproductive years with FPHL and PCOS deserve a specific note. PCOS drives androgen excess that worsens FPHL. ACOG Practice Bulletin No. 194 identifies anti-androgens, including finasteride, as second-line treatment for PCOS-related hyperandrogenism. Sermorelin in PCOS is not guideline-supported; however, some clinicians use it off-label for body composition in women with PCOS who have low IGF-1. If you have PCOS and are considering either drug, the androgen-GH axis overlap described above is directly relevant to your biology.

Perimenopause (Approximately Ages 45 to 55)

This is the most likely life stage at which a woman might plausibly receive both drugs. GH pulse amplitude and IGF-1 decline progressively from the mid-30s, accelerating around menopause. Women lose approximately 14% of their GH secretory capacity per decade after age 30. At the same time, the relative rise in androgens (as estrogen falls) drives FPHL in many perimenopausal women.

Finasteride 1 mg has been studied in postmenopausal women with FPHL. The Rushton et al. Trial found no significant benefit in postmenopausal women with FPHL over 12 months, though other smaller case series have shown benefit. The evidence base is thin. Sermorelin in perimenopausal women is entirely off-label with no published RCT data in this population.

Perimenopausal women on this combination should have IGF-1, free testosterone, DHEA-S, and estradiol measured at baseline and every 3 months for the first year.

Postmenopause

Postmenopausal women are no longer at risk of finasteride-related fetal exposure. GH decline is maximal after menopause. If IGF-1 is documented low and FPHL is progressive, the combination may be considered on a case-by-case basis with the monitoring above. The Menopause Society (formerly NAMS) does not have a position statement on GH secretagogues in postmenopausal women, reflecting the absence of guideline-level evidence.

Pregnancy and Lactation Safety

Finasteride in pregnancy: contraindicated. The FDA label carries a boxed warning for pregnant women or women who may become pregnant. Even crushed tablet contact with skin may pose a risk. The label states that finasteride is contraindicated in women who are or may become pregnant. A highly effective non-hormonal or hormonal contraceptive method is required for any woman of reproductive potential who is prescribed finasteride.

Sermorelin in pregnancy: avoid. Sermorelin is Pregnancy Category C. No adequate, well-controlled studies exist in pregnant women. Animal studies showed some fetal harm at suprapharmacologic doses. The prescribing information for sermorelin advises caution and recommends stopping the drug if pregnancy occurs.

Lactation. Neither finasteride nor sermorelin has adequate human lactation transfer data. Finasteride is lipophilic and has a moderate volume of distribution (approximately 76 L), raising theoretical concern for milk transfer. Sermorelin, as a peptide, would largely be degraded in the infant's gut, but no pharmacokinetic study of sermorelin in breast milk exists. Given the absence of safety data, both drugs should be avoided while breastfeeding.

Contraception requirement. Any woman of reproductive age prescribed finasteride for FPHL or PCOS must use a reliable contraceptive method throughout treatment and for at least one month after stopping, given the drug's 6- to 8-hour half-life and tissue accumulation in the prostate (or analogous androgenic tissue). Sermorelin should also be stopped at least 30 days before any planned conception attempt, as a precaution.

Who This Combination Is Right For (and Who It Is Not)

Potentially Appropriate

• Postmenopausal women with documented low IGF-1 AND progressive FPHL AND no contraindications to either drug.
• Perimenopausal women with a documented androgen-excess pattern (elevated free testosterone or DHEA-S) contributing to FPHL, who understand both drugs are off-label in this context and consent to close monitoring.
• Women who have failed topical minoxidil for FPHL and have a clinician experienced in compounded peptide therapy.

Not Appropriate

• Women who are pregnant, trying to conceive, or breastfeeding.
• Women with active malignancy, particularly hormone-sensitive cancers, given the androgen axis manipulation of both agents.
• Women with significantly elevated IGF-1 at baseline (sermorelin contraindicated).
• Women with active pituitary disease, hypothalamic tumors, or prior cranial irradiation (sermorelin contraindicated per standard compounding guidance).
• Women taking insulin, oral hypoglycemics, or glucocorticoids without close endocrine monitoring, as sermorelin increases GH, which is counter-regulatory to insulin.

Monitoring Protocol When Both Drugs Are Used

A structured monitoring plan reduces the risk of missing both underdosing (sermorelin not raising IGF-1 adequately due to low androgen tone) and overdosing (excess IGF-1 signaling).

Baseline (before starting either drug):

• Fasting IGF-1
• Free and total testosterone
• DHEA-S
• DHT (if available in your lab panel)
• Complete metabolic panel (glucose, liver enzymes)
• Thyroid function (TSH, free T4), because hypothyroidism blunts GH response independently
• Hair pull test and global photography if treating FPHL

At 6 to 8 weeks:

• Fasting glucose (GH is diabetogenic; monitor early)
• IGF-1 to check sermorelin response

At 3 months:

• Full repeat of baseline labs
• Assess FPHL response clinically

At 6 and 12 months:

• Repeat all above
• Consider dose adjustment of sermorelin if IGF-1 remains below the age-matched reference range despite consistent use

AACE Clinical Practice Guidelines for growth hormone deficiency in adults recommend targeting IGF-1 in the middle of the age- and sex-adjusted normal range, not at the upper limit, to minimize adverse effects including fluid retention, arthralgia, and insulin resistance.

Practical Drug Interaction Counseling Points

If your clinician prescribes both sermorelin and finasteride, here is what to track:

• Take finasteride at the same time each day, with or without food. Sermorelin is typically injected subcutaneously at bedtime to mimic the natural GH surge during slow-wave sleep.
• Do not adjust either drug dose without clinician guidance. Lowering finasteride dose to manage side effects (libido changes, breast tenderness) will also change the DHT-to-testosterone ratio and may alter your IGF-1 trajectory.
• If you start or stop any other medication that affects androgen levels (spironolactone, oral contraceptives, DHEA supplements, testosterone cream), inform your prescriber immediately because these will shift the pharmacodynamic overlap described above.
• Report any new joint pain, swelling, or fluid retention promptly. These are the most common adverse effects of excess GH stimulation and require IGF-1 measurement.
• Report any breast changes. Both androgen manipulation and GH signaling have theoretical mammary effects; finasteride has been associated with gynecomastia in men and rare breast tenderness in women.

What the Evidence Gap Means for You

Women have been systematically under-represented in drug interaction studies. Most CYP enzyme and PK/PD interaction data were generated in male subjects, then extrapolated. For this specific combination, sermorelin was originally studied almost exclusively in children and in men with adult-onset GH deficiency. Finasteride's key trials enrolled men with benign prostatic hyperplasia or male pattern baldness.

The female-specific data are extrapolated, not directly studied. That honesty is not a reason to avoid either drug outright, but it is a reason to insist on individualized monitoring, to document your lab trajectories, and to revisit the decision at every 3-month check-in.

A 2020 Cochrane review on interventions for female androgenetic alopecia found insufficient evidence to support or refute finasteride use in premenopausal women, explicitly noting the paucity of high-quality trials. No comparable Cochrane review on sermorelin in women exists.

Other Sermorelin Drug Interactions Worth Knowing

While finasteride's interaction with sermorelin is indirect, a handful of drug classes produce more direct pharmacodynamic effects on the GH axis that women using sermorelin should know about:

Glucocorticoids. Chronic glucocorticoid use (prednisone, dexamethasone) suppresses GH secretion and blunts sermorelin response. Women on long-term steroids for autoimmune conditions should expect attenuated IGF-1 response.

Thyroid hormone. Hypothyroidism significantly reduces GH pulsatility. Untreated hypothyroidism can reduce IGF-1 by up to 30% independent of GH secretagogue use. Optimize thyroid status before starting sermorelin.

Insulin and oral hypoglycemics. GH is a counter-regulatory hormone that raises blood glucose. Adding sermorelin to insulin or metformin therapy requires glucose monitoring, especially in women with PCOS-related insulin resistance.

Estrogen (oral route). Oral estrogen reduces IGF-1 by approximately 20 to 30% compared with transdermal estrogen by inducing hepatic IGF-1 resistance. Women on oral hormone therapy (HRT) may need higher sermorelin doses to reach the same IGF-1 target as women on transdermal routes. This is a clinically meaningful distinction for perimenopausal and postmenopausal women.

Somatostatin analogues. Octreotide and lanreotide directly counteract sermorelin's mechanism. These are rarely co-prescribed in the same clinical context, but if you have a neuroendocrine condition requiring one, sermorelin is contraindicated.